<DOC>
	<DOCNO>NCT01471782</DOCNO>
	<brief_summary>The purpose study determine dose bispecific T cell engager blinatumomab ( MT103 ) pediatric adolescent patient relapsed/refractory acute lymphoblastic leukemia ( ALL ) ass whether dose blinatumomab effective .</brief_summary>
	<brief_title>Clinical Study With Blinatumomab Pediatric Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Childhood acute lymphoblastic leukemia ( ALL ) type cancer blood bone marrow bone marrow make many abnormal immature lymphocytes . Blinatumomab bispecific single-chain antibody construct design link B cell T cell result T cell activation cytotoxic T cell response cluster differentiation ( CD ) 19 express cell . The purpose study investigate pharmacokinetics ( PK ) , pharmacodynamics ( PD ) safety escalate dos blinatumomab pediatric adolescent patient relapsed/refractory B-precursor ALL , select dose investigate efficacy safety dose blinatumomab above-mentioned patient population . The phase 1 part study include evaluation four dose level blinatumomab comprehensive PK/PD assessment separate 2 part : - Phase 1 dose evaluation/escalation part define recommend phase 2 dose blinatumomab patient age 2 17 year - Phase 1 PK expansion part patient age &lt; 18 year assess PK/PD recommend phase 2 dose . In part additional participant enrol ensure 6 patient 2 old age group ( 2-6 7-17 year ) analyze PK recruitment infant &lt; 2 year age begin . In phase 2 extension cohort ( efficacy phase ) study , eligible participant le 18 year enrol accord two-stage design receive blinatumomab recommend dose level ( 5/15 μg/m²/day ) . The study consist screening period , treatment period , End Core Study visit 30 day last dose study medication . A treatment cycle consist continuous intravenous ( cIV ) infusion 4 week follow treatment-free interval 2 week . Participants achieve complete remission ( CR ) within 2 cycle treatment could receive 3 additional consolidation cycle blinatumomab . Instead consolidation cycle blinatumomab , participant could withdraw blinatumomab treatment receive chemotherapy allogeneic HSCT early first cycle , discretion investigator . After last treatment cycle End Core Study visit , participant follow efficacy survival 24 month treatment start . Participants suffer hematological relapse B-precursor ALL follow-up period ( least 3 month completion treatment ) possibility retreatment blinatumomab .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Blinatumomab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Morphologic evidence Bprecursor ALL &gt; 25 % blast bone marrow ( M3 ) study enrolment Age le 18 year enrollment Relapsed/refractory disease : Second later bone marrow relapse , Any marrow relapse allogeneic hematopoietic stem cell transplantation ( HSCT ) , Refractory treatment : Patients first relapse must fail achieve CR follow full standard reinduction chemotherapy regimen least 4 week duration . Patients achieve first remission must fail full standard induction regimen Karnofsky performance status equal 50 % patient equal 16 year Lansky Performance Status ( LPS ) equal 50 % patient le 16 year Organ function requirement : All patient must adequate renal liver function Active acute extensive chronic graftversushost disease ( GvHD ) Immunosuppressive agent prevent treat GvHD within 2 week prior blinatumomab treatment Evidence current central nervous system ( CNS ) involvement ALL ( CNS 2 , CNS 3 ) testicular involvement ALL History relevant CNS pathology current relevant CNS pathology History autoimmune disease potential CNS involvement current autoimmune disease Any HSCT within 3 month prior blinatumomab treatment Cancer chemotherapy within 2 week prior blinatumomab treatment ( except intrathecal chemotherapy and/or low dose maintenance therapy vinca alkaloid , mercaptopurine , methotrexate , glucocorticoid ) Chemotherapy related toxicity n't resolve less equal Grade 2 Radiotherapy within 2 week prior blinatumomab treatment Immunotherapy ( e.g . rituximab , alemtuzumab ) within 6 week prior blinatumomab treatment Any investigational product within 4 week prior study entry Previous treatment blinatumomab Active severe infection , concurrent disease medical condition could exacerbate treatment would seriously complicate compliance protocol Known infection human immunodeficiency virus ( HIV ) chronic infection hepatitis B virus ( HbsAg positive ) hepatitis C virus ( antiHCV positive )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ALL</keyword>
	<keyword>relapse , refractory B-precursor ALL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Lymphoid</keyword>
	<keyword>Precursor Cell Lymphoblastic Leukemia</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Antibodies , Bispecific</keyword>
</DOC>